Alzheimer's Disease: Treatment Strategies and Their Limitations.
Open accessThe DOI matches its Crossref record; 274 of the 279 references it cites were found in a registry or an index; 114 of the 190 sources its claims cite were checked for support.
Abstract
Current drug treatments have only symptomatic effects, and disease-modifying treatments are not yet available. Drug delivery to the central nervous system remains a complex process and represents a challenge.
Overview
CoChat Summary
TL;DR
This review argues that Alzheimer’s disease is a progressive, multifactorial disorder for which current drugs are only symptomatic and not curative, making prevention and earlier intervention the main priorities. It emphasizes modifiable risk factors, lipid-based prevention, and soft nanoparticles—especially liposomes and exosomes—as promising ways to improve delivery across the blood–brain barrier.
Key findings
- AD is described as a continuum with preclinical, MCI due to AD, and dementia stages; the first neuropathological signs can appear 15–20 years before disease onset.
- The paper states that more than 30% of AD cases could be due to modifiable risk factors, and cites a report identifying 12 modifiable risk factors that account for about 40% of dementias worldwide.
- Current approved AD drugs are four symptomatic medications: donepezil, memantine, galantamine, and rivastigmine; the paper says their effects are only partial and temporary.
- The review highlights soft nanoparticles as delivery tools: liposomes and exosomes are presented as capable of crossing the BBB, and intranasal administration is described as a promising route; however, no nanosystem has passed the clinical development stage for intranasal delivery.
Methods
- Narrative review of the literature on AD clinical spectrum, pathophysiology, risk factors, models, treatments, and delivery strategies.
- Synthesizes findings from human studies, clinical trials, in vitro models, animal models, and nanotechnology/drug-delivery studies cited throughout the paper.
- Main analysis is qualitative and comparative rather than experimental, organizing evidence into prevention, modeling, treatment limitations, and BBB-delivery approaches.
Limitations
- Stated by the paper: current treatment effects are symptomatic, partial, and temporary, and there is no curative treatment or disease-modifying treatment yet.
- Stated by the paper: evidence for prevention and intranasal approaches is limited by short study durations, inconsistent results, and the fact that no nanosystem has passed clinical development.
- Evident from the text: this is a broad review, so its conclusions depend on heterogeneous prior studies and do not present new primary data or a formal meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Alzheimer’s Disease spectrum. (A) Key players in the pathogenesis of Alzheimer’s disease (AD). Reprinted with permission from [12]. Copyright 2009, Nature Publishing Group. (B) Aging and metabolic diseases alteration of brain metabolism, which progressively causes AD. Reprinted from [65], Copyright 2017, Yonsei University College of Medicine. (C) Differential diagnosis of AD using neuroimaging biomarkers. Reprinted with permission [66]. Copyright 2009, Elsevier.](https://figures.cochat.ai/paper-figures/e8086ea2fb2c44a18e66c883790856eb/alzheimer-s-disease-treatment-strategies-and-their-limitations-figure-1.jpg)
![Figure 2 3D in vitro models of Alzheimer’s disease. (A) PLGA scaffold encapsulating iPSC-derived NPCs, shown by proliferation marker Ki67, undifferentiated cell marker Nestin, and neural differentiation marker TuJ1. (i–iii) Cross-section ofthe 3D microfiber scaffold showing cell infiltration, distribution and differentiation. (iv,v) cell proliferation and differentiation. (vi) SEM image of the scaffold cross-section. Reprinted with permission from [134]. Copyright 2020, The Royal Society of Chemistry. (B) Reduction of neural plasticity in neural stem cells as a result of Aβ plaques. Image (i,iii) indicate healthy neural stem cells, which can form new synaptic connections, shown in (iii). Image (ii,iv) have the Aβ plaques incorporated in the hydrogel and are unable to form new synaptic connections. Reprinted with permission from [135]. Copyright 2018, Elsevier. (C) 3D spheroids derived from human neural progenitor cells, displaying Aβ pathology (shown in blue). Green and Red channels depict the neuronal cells and differentiated neurons, respectively. Reprinted from [138]. Copyright 2020, Nature Portfolio. (D) Acoustofluidic platform to assemble cells and Aβ oligomers into neuro-spheroids representing AD. Reproduced with permission of The Royal Society of Chemistry [139]. (i) cross-section of the 3D microfiber scaffold after sectioning (dotted line indicates the top surface of the 3D scaffold); (ii,iii) cell infiltration, distribution and differentiation of iPSC-derived NPCs (8529 cell line) inside the 3D scaffold as assessed via staining for TuJ1 (green) and Nestin (red) markers on D13; (iv) cell proliferation assessed by the Ki67 (green) marker and (v) cell differentiation with neurite formation indicated by the TuJ1 (red) marker of hESC-derived NPCs on D13; nuclei were counterstained with DAPI (blue); (vi) SEM image of the scaffold cross-section showing cell morphology and attachment on microfibers at 2000× magnification.](https://figures.cochat.ai/paper-figures/e3a8b9b3bac94ab19d6a9627039ad12d/alzheimer-s-disease-treatment-strategies-and-their-limitations-figure-2.jpg)

Verification
Claims the paper makes
73 Valid · 2 Not valid · 37 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Research has shown that in the world, more than 30% of AD cases could be due to modifiable risk factors, which could provide interesting and promising targets for prevention strategies to reduce the risk of AD-related cognitive decline and perhaps ND in general [3,20,21].”
§ Alzheimer’s Disease: Treatment Strategies and Their Limitations > 1. Introduction
What the sources say
- Partly supportedcites [3] Livingston, 2020, Dementia Prevention, Intervention, and Care: 2020 Report of the Lancet Commission, Lancet sourceExperimental — accuracy not yet measured
The Executive summary reports that 12 modifiable risk factors account for around 40% of worldwide dementias, and “Dementia in LMIC” gives an earlier estimate of 35%, assuming causation. Those estimates concern dementia overall, not Alzheimer's disease cases specifically, so they do not establish the claim at that level of specificity. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [20] Norton, 2014, Potential for Primary Prevention of Alzheimer’s Disease: An Analysis of Population-Based Data, Lancet Neurol. source
- Partly supportedcites [21] Livingston, 2017, Dementia Prevention, Intervention, and Care, Lancet sourceExperimental — accuracy not yet measured
The Abstract says that around one third of dementia may theoretically be preventable through addressing potentially reversible risk factors. That supports the approximate proportion and prevention premise, but it refers to dementia overall, not specifically to worldwide Alzheimer's disease cases. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, nanotechnology can be used to improve the bioavailability of PUFA in the form of NL [34,37].”
§ Alzheimer’s Disease: Treatment Strategies and Their Limitations > 1. Introduction
What the sources say
- Partly supportedcites [34] Kaushik, 2018, Personalized Nanomedicine for CNS Diseases, Drug Discov. Today sourceExperimental — accuracy not yet measured
The Alzheimer’s disease section describes liposome-based nanocarriers for delivering other compounds, including curcumin. It does not say that nanoliposomes improve PUFA bioavailability; searches for PUFA, polyunsaturated fatty acids, and fatty-acid bioavailability found no such passage in our copy. (LLM, conf=0.79)
- Partly supportedcites [37] Ross, 2018, Liposome Delivery Systems for the Treatment of Alzheimer’s Disease, Int. J. Nanomed. sourceExperimental — accuracy not yet measured
The Stealth liposomes section (page unavailable) says modified liposomes can improve circulation time, supporting the general delivery-system premise. The copy does not say that nanoliposomes improve the bioavailability of PUFAs specifically; searches for PUFA, polyunsaturated fatty acids, and fatty-acid bioavailability found no such passage. (LLM, conf=0.79)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This could explain why part of the risk factors for cardiovascular disease are in common with AD, including hypertension, dyslipidemia, diabetes, obesity, dietary factors, smoking, and physical activity (Figure 1B).”
§ Alzheimer’s Disease: Treatment Strategies and Their Limitations > 2. Understanding Clinical Spectrum of AD > 2.4. Risk Factors of SAD
What the sources say
- Not checked — no full text of the sourcecites [1] Scheltens, 2016, Alzheimer’s Disease, Lancet source
- Partly supportedcites [22] Dubois, 2016, Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria, Alzheimer’s Dement. sourceExperimental — accuracy not yet measured
Section 3.4 identifies hypertension, obesity, diabetes, physical inactivity, and smoking as AD risk factors; section 3.5 discusses diet and exercise in relation to AD risk. The paper also groups cardiovascular and lifestyle factors as modifiable AD risks, but our copy does not identify dyslipidemia as an AD risk factor, so the full list is not supported. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [100] Whitmer, 2005, Midlife Cardiovascular Risk Factors and Risk of Dementia in Late Life, Neurology source
- Partly supportedcites [101] Zlokovic, 2011, Neurovascular Pathways to Neurodegeneration in Alzheimer’s Disease and Other Disorders, Nat. Rev. Neurosci. sourceExperimental — accuracy not yet measured
The Alzheimer’s disease section (page not provided) says that cerebrovascular and Alzheimer’s disease risk factors substantially overlap, and specifically names midlife diabetes, hypertension, and obesity. It does not identify dyslipidemia, dietary factors, smoking, or physical activity as shared risk factors. (LLM, conf=0.86)
- Partly supportedcites [102] Yu, 2020, Evidence-Based Prevention of Alzheimer’s Disease: Systematic Review and Meta-Analysis of 243 Observational Prospective Studies and 153 Randomised Controlled Trials, J. Neurol. Neurosurg. Psychiatry sourceExperimental — accuracy not yet measured
The Results (Figure 5) identify hypertension, diabetes, midlife obesity, physical exercise, and smoking as factors relevant to Alzheimer’s disease prevention. The passages do not establish dyslipidemia or dietary factors as Alzheimer’s disease risk factors, so they do not support the full list of shared cardiovascular and Alzheimer’s risk factors. (LLM, conf=0.85)
- Partly supportedcites [103] Edwards, 2019, Modifiable Risk Factors for Alzheimer’s Disease, Front. Aging Neurosci. sourceExperimental — accuracy not yet measured
The Vascular Diseases section (page unavailable) explicitly identifies hypertension, diabetes, and hypercholesterolemia as risks shared by cardiovascular disease and AD; its Smoking section also links smoking to cardiovascular disease and dementia. The paper discusses diet and obesity in relation to diabetes and AD, but does not establish every item in the citing sentence as a shared cardiovascular–AD risk factor. Its Physical Activity section says it remains unknown whether exercise reduces the risk of developing AD. (LLM, conf=0.86)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The main risk factor for SAD is age. Indeed, increased life expectancy is correlated with a higher probability of developing neurodegenerative diseases, including AD [89,90].”
§ Alzheimer’s Disease: Treatment Strategies and Their Limitations > 2. Understanding Clinical Spectrum of AD > 2.4. Risk Factors of SAD
What the sources say
- Supportedcites [89] Hebert, 2010, Change in Risk of Alzheimer Disease over Time, Neurology source
The Discussion (p. 790) calls age an “extremely important predictor of AD risk,” supporting the claim that age is a principal risk factor. The paper studies AD in a community population rather than separately identifying sporadic cases, but the citing sentence makes a broad background point, not a subtype-specific estimate. (LLM, conf=0.86)
- Not matchedcites [90] Prince, M.J., Guerchet, M.M., and Prina, M. (2022, June 04). The Epidemiology and Impact of Dementia: Current State and Future Trends. WHO Thematic Briefing. Available online: https://hal.archives-ouvertes.fr/hal-03517019.
We searched by its title and found no matching paper.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Soft NP, such as nanoliposomes (NL) or exosomes, represent one of the most effective drug delivery processes to be able to protect therapeutic agents and deliver them to the target tissues [32,33].”
§ Alzheimer’s Disease: Treatment Strategies and Their Limitations > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [32] Agrawal, 2017, Recent Advancements in Liposomes Targeting Strategies to Cross Blood-Brain Barrier (BBB) for the Treatment of Alzheimer’s Disease, J. Control. Release source
- Partly supportedcites [33] Saint-Pol, J., Gosselet, F., Duban-Deweer, S., Pottiez, G., and Karamanos, Y. (2020). Targeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles. Cells, 9. sourceExperimental — accuracy not yet measured
The Introduction says lipid-based nanoparticles can enclose and protect therapeutic compounds and be designed to target the brain. Section 4 describes exosomes delivering therapeutic cargo to the brain. The paper does not establish that nanoliposomes and exosomes are among the most effective delivery methods, or address delivery to target tissues generally. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
68 more claims · 31 with their cited sources checked
Create a free account to see all 157 claims and to verify the 10 references still open.
- It may state two separate claims as one. 73
- Probably not a substantial claim. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It becomes a comprehensive care paradigm when pharmacological therapies are combined with lifestyle changes, cognitive training, and psychosocial support.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [221]
Experimental — accuracy not yet measuredIn the citing paper
“This approach is adaptable enough to be customized for every single patient, ensuring optimal treatment outcomes [220,221].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [221]
In the citing paper
“These drugs are used for all stages of AD, but inhibition of cholinesterase enzymes works best at the early stage of AD [9, 12].”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [9]
In the citing paper
“Current therapeutics to ameliorate and control the cognitive and behavioral symptoms by targeting the NMDA receptor prevent Ca2+ induced excitotoxicity [2, 9–11], and memantine was approved for this purpose in 2003.”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [9]
In the citing paper
“Memantine is more effective in providing cognitive and behavioral benefits and approved for patients with moderate to severe AD as monotherapy or combination therapy with donepezil [9, 12].”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [9]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“A history of head trauma and hearing loss may favor the onset of AD [3,102,116].”
Cited work 10.1016/s0140-6736(20)30367-6 · retracted 2023-05-01 · notice 10.1016/s2468-2667(23)00083-x · this paper published 2022-11-12
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 5×
“A history of head trauma and hearing loss may favor the onset of AD [3,102,116].”
BackgroundInfluentialRetractedDiagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“The NFT then evolves in the external part of the temporal lobe before spreading to the posterior cortical associative areas and the entire cortex [6].”
BackgroundNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · cited 6×
“The presence of biomarkers can be used to indicate the severity of the AD [7,71]: decreased CSF Aβ levels, increased CSF Tau and/or P-Tau levels, cortical thinning and hippocampal atrophy based on MRI, hypometabolism or hypoperfusion of posterior cingulate and temporoparietal cortex (FDG-PET), and detection of cortica…”
InfluentialAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“The hypothesis of the amyloid cascade suggests that the anomalous accumulation of Aβ peptide and formation of amyloid plaques induce NFT formation and makes neurons more sensitive to neurotoxic effects and neuronal death [57].”
BackgroundDementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072 · cited 1×
“Research has shown that in the world, more than 30% of AD cases could be due to modifiable risk factors, which could provide interesting and promising targets for prevention strategies to reduce the risk of AD-related cognitive decline and perhaps ND in general [3,20,21].”
BackgroundRecent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282 · cited 1×
“Moreover, NL can be used to encapsulate a variety of molecules, including hydrophilic or hydrophobic drugs, proteins, or DNA [40].”
BackgroundStructure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185 · cited 1×
“Because of this, the increased dosage is necessary, which could also increase the possibility of secondary undesired effects [160,161].”
BackgroundDelivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 14×
“In this work, we review the clinical and physiopathology of SAD, including research models of AD, followed by a discussion of current treatments focusing on prevention strategies and the use of soft NP such as NL and exosome as innovative approaches for a preventive strategy in reducing the risk of AD.”
BackgroundInfluentialSoluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“Oligomers of soluble Aβ could interact with the cell surface potentially by direct membrane interaction or by binding a putative receptor leading to impairment of signal-transduction cascades, modified neuronal activities, and release of neurotoxic mediators by microglia, leading to early altered synaptic functions an…”
BackgroundDiffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664 · cited 2×
“Bangha iscovered lip omes when he noticed that phospholipids, when surrounded by an aqueous medium, formed a closed bilayer [194,195].”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 2×
“manifest AD, which indicates that other as yet to be identified determinants (genetic or otherwise) may be involved in AD development [88].”
BackgroundHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 2×
“Indeed, these are found first in the neocortex, followed by the hippocampal region, the subcortical nuclei, and finally, in the cerebellum [5].”
BackgroundApolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“The ε4 has been linked to changes in neurotoxic and neuroprotective mechanisms, including Aβ peptide metabolism, aggregation, toxicity, tauopathy, synaptic plasticity, lipid transport, vascular integrity, and neuroinflammation [96].”
BackgroundAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · cited 1×
“Indeed, AD is represented as a continuum that evolves in three stages, asymptomatic (preclinical AD), predementia (MCI due to AD), and dementia (due to AD) [22,70,71].”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052 · cited 1×
“It is characterized by the appearance of multiple cognitive deficits progressively increasing with time, including memory deterioration in the acquisition of new information and in the recovery of information [13], as well as the association of one or more of the following dysfunctions: aphasia, apraxia, agnosia, or d…”
BackgroundNeurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969 · cited 1×
“Although the brain represents 2% of the total body weight, 20% of body oxygen consumption and 25% of the glucose consumption can be attributed to this organ [101,104].”
BackgroundThe projected effect of risk factor reduction on Alzheimer's disease prevalence
Barnes, D. E., & Yaffe, K. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70072-2 · Cited by 2,666
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Potential for primary prevention of Alzheimer's disease: an analysis of population-based data
Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K., & Brayne, C. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70136-x · Cited by 2,466 · cited 2×
“Moreover, excessive consumption of tobacco and alcohol increases cognitive impairments [20].”
BackgroundVillemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279 · cited 1×
“The lesions form slowly without clinical expression (no complaints from patients about troubles in everyday life) [12,14,15].”
BackgroundLiposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156 · cited 1×
“Liposomes have been researched for more than five decades, to the point where they are well-established drug delivery vectors, resulting in the marketing authorization of several clinically approved liposomal-based products [203].”
BackgroundExosomes as drug delivery vehicles for Parkinson’s disease therapy
Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A. V., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.033 · Cited by 2,009 · cited 1×
“A formulation of catalase loaded in exosomes accumulated in Parkinson’s disease mouse brain and provided significant neuroprotective [239].”
BackgroundThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990 · cited 1×
“The first neuropathological signs of AD can occur 15 or 20 years before the disease begins [74].”
BackgroundPreclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · cited 4×
“Indeed, the new diagnostic criteria require the use of cerebrospinal fluid (CSF) biomarkers, including total and hyperphosphorylated Tau protein as well as Aβ42 or Aβ42/Aβ40 ratio and positron emission tomography (PET) of τau and amyloid to attribute a probability (high, medium, or low) of the underlying AD-related ne…”
BackgroundMethodInfluentialThe cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918 · cited 2×
“This includes a progressive loss of cholinergic innervation caused by dendritic, synaptic, and axonal degeneration [53,62].”
Background2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864 · cited 1×
“The presence of biomarkers can be used to indicate the severity of the AD [7,71]: decreased CSF Aβ levels, increased CSF Tau and/or P-Tau levels, cortical thinning and hippocampal atrophy based on MRI, hypometabolism or hypoperfusion of posterior cingulate and temporoparietal cortex (FDG-PET), and detection of cortica…”
BackgroundSystematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
Modeling physiological events in 2D vs. 3D cell culture
Duval, K., Grover, H., Han, L.-H., Mou, Y., Pegoraro, A. F., Fredberg, J., & Chen, Z. (2017) · Physiology · doi:10.1152/physiol.00036.2016 · Cited by 1,849 · cited 1×
“These models are easy to maintain and cost-effective but do not allow the study of glia-neuron communication and crosstalk [119].”
BackgroundBangham, A. D., & Horne, R. W. (1964) · Journal of Molecular Biology · doi:10.1016/s0022-2836(64)80115-7 · Cited by 1,809 · cited 2×
“Bangha iscovered lip omes when he noticed that phospholipids, when surrounded by an aqueous medium, formed a closed bilayer [194,195].”
BackgroundDrug delivery systems: An updated review
Tiwari, G., Tiwari, R., Bannerjee, S., Bhati, L., Pandey, S., Pandey, P., & Sriwastawa, B. (2012) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.96920 · Cited by 1,671
Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells
Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.180 · Cited by 1,666
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600 · cited 3×
“With the lower volume of hydration in the liposome core, hydrophilic molecules are entrapped with a lower efficiency than hydrophobic molecules [42].”
BackgroundBehavioral and psychological symptoms of dementia
Cerejeira, J., Lagarto, L., & Mukaetova-Ladinska, E. B. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00073 · Cited by 1,425
Physical principles of membrane organization
Israelachvili, J. N., Marčelja, S., & Horn, R. G. (1980) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583500001645 · Cited by 1,404 · cited 2×
“Electrostatic int ractions, such as van der Wa l forces and hy o e bonding, further enhance this formation [197,198].”
BackgroundAlzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357
Zhuang, X., Xiang, X., Grizzle, W., Sun, D., Zhang, S., Axtell, R. C., Ju, S., Mu, J., Zhang, L., Steinman, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.164 · Cited by 1,356 · cited 1×
“Other researchers used intranasal injections to successfully deliver exosomes to the brain of mice [236].”
BackgroundNeural mechanisms of ageing and cognitive decline
Bishop, N. A., Lu, T., & Yankner, B. A. (2010) · Nature · doi:10.1038/nature08983 · Cited by 1,323
Assessment and management of behavioral and psychological symptoms of dementia
Kales, H. C., Gitlin, L. N., & Lyketsos, C. G. (2015) · BMJ · doi:10.1136/bmj.h369 · Cited by 1,247
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239 · cited 1×
“This approach is increasingly used in clinical studies for the treatment of neurological diseases [251] like AD [32,252], brain injuries [253], and autism [254].”
MethodMidlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238 · cited 2×
“Cardiovascular damage is a risk factor for neurodegenerative diseases, and since the brain is supplied by a large network of blood vessels, a healthy cardiovascular system can be considered neuroprotective [100].”
BackgroundIntranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214 · cited 1×
“Even if the intranasal mechanisms of drugs to the brain are not yet completely understood, IN delivery represents a promising pathway of administration and should be investigated for future pre-clinical and clinical studies in the treatment of neurological diseases such as AD [255].”
BackgroundDifferential aging of the brain: Patterns, cognitive correlates and modifiers
Raz, N., & Rodrigue, K. M. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.07.001 · Cited by 1,195
Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
Reitz, C., & Mayeux, R. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,181
Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease
Kivipelto, M., Mangialasche, F., & Ngandu, T. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0070-3 · Cited by 1,173
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease
Giannakopoulos, P., Herrmann, F. R., Bussière, T., Bouras, C., Kövari, E., Perl, D. P., Morrison, J. H., Gold, G., & Hof, P. R. (2003) · Neurology · doi:10.1212/01.wnl.0000063311.58879.01 · Cited by 1,118 · cited 2×
“This topography of the lesions corresponds to the evolution of the symptoms of AD [48].”
BackgroundThe cholinergic system in aging and neuronal degeneration
Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047 · cited 1×
“This includes a progressive loss of cholinergic innervation caused by dendritic, synaptic, and axonal degeneration [53,62].”
BackgroundReview Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029
Nau, R., Sörgel, F., & Eiffert, H. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00007-10 · Cited by 1,026 · cited 1×
“This discovery was later confirmed by his student Edwin Goldman in 1913 [190].”
BackgroundBiomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002 · cited 1×
“Indeed, the new diagnostic criteria require the use of cerebrospinal fluid (CSF) biomarkers, including total and hyperphosphorylated Tau protein as well as Aβ42 or Aβ42/Aβ40 ratio and positron emission tomography (PET) of τau and amyloid to attribute a probability (high, medium, or low) of the underlying AD-related ne…”
BackgroundYang, T., Martin, P., Fogarty, B., Brown, A., Schurman, K., Phipps, R., Yin, V. P., Lockman, P., & Bai, S. (2015) · Pharmaceutical Research · doi:10.1007/s11095-014-1593-y · Cited by 975 · cited 1×
“Yang and coworkers reported that the delivery of anticancer drugs encapsulated in exosomes across the BBB significantly decreased the fluorescent intensity of xenotransplanted cancer cells and tumor growth markers [238].”
BackgroundIntranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.
Guastella, A. J., Einfeld, S. L., Gray, K. M., Rinehart, N. J., Tonge, B. J., Lambert, T. J., & Hickie, I. B. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.020 · Cited by 962 · cited 1×
“This approach is increasingly used in clinical studies for the treatment of neurological diseases [251] like AD [32,252], brain injuries [253], and autism [254].”
MethodBlood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950
Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy
Olazarán, J., Reisberg, B., Clare, L., Cruz, I., Peña-Casanova, J., del Ser, T., Woods, B., Beck, C., Auer, S., Lai, C., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000316119 · Cited by 937
Alzheimer’s disease: risk factors and potentially protective measures
Silva, M. V. F., Loures, C. D. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0524-y · Cited by 937 · cited 1×
“Other factors are involved, including nutrition and other environmental parameters that can protect cardiovascular pathologies, thereby reducing AD risk [87].”
BackgroundEssential fatty acids in growth and development
Innis, S. M. (1991) · Progress in Lipid Research · doi:10.1016/0163-7827(91)90006-q · Cited by 921 · cited 1×
“The brain has significant levels of omega-3 polyunsaturated fatty acids (n-3 PUFA), incorporated into phospholipids, amphiphilic molecules that are components of neuronal membranes [23,24].”
BackgroundMechanisms of action of docosahexaenoic acid in the nervous system
Salem, N., Litman, B., Kim, H., & Gawrisch, K. (2001) · Lipids · doi:10.1007/s11745-001-0805-6 · Cited by 919 · cited 1×
“DHA is known for its neuroprotective effects and synaptic plasticity and has a key role in aging, memory, vision, and corneal nerve regeneration [181].”
BackgroundZhao, Q.-F., Tan, L., Wang, H.-F., Jiang, T., Tan, M.-S., Tan, L., Xu, W., Li, J.-Q., Wang, J., Lai, T.-J., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.069 · Cited by 916 · cited 1×
“In many cases, people also have neuropsychiatric disorders such as apathy (49%), depression (42%), aggression (40%), anxiety (39%), and sleep disorders (39%) [81].”
BackgroundThe Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Novel applications of liposomes
Lasic, D. (1998) · Trends in Biotechnology · doi:10.1016/s0167-7799(98)01220-7 · Cited by 867 · cited 2×
“Electrostatic int ractions, such as van der Wa l forces and hy o e bonding, further enhance this formation [197,198].”
BackgroundClassification and Epidemiology of MCI
Roberts, R., & Knopman, D. S. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.07.003 · Cited by 839 · cited 1×
“Many clinical studies are in progress to address this issue [79,80].”
BackgroundUnderstanding the impact of sex and gender in Alzheimer’s disease: A call to action
Nebel, R. A., Aggarwal, N. T., Barnes, L. L., Gallagher, A., Goldstein, J. M., Kantarci, K., Mallampalli, M. P., Mormino, E. C., Scott, L., Yu, W. H., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.008 · Cited by 839 · cited 1×
“To understand the influence of gender differences, studies are needed to determine gender influence on biomarker evolution across the life span, including cognitive abilities, neuroimaging, CSF, and blood-based biomarkers of AD, particularly at earlier ages [98].”
BackgroundCrossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837 · cited 2×
“The BBB’s main role is to separate the blood that circulates in the body, and that might contain toxic foreign molecules from the brain’s extracellular fluid present in the CNS [189].”
BackgroundTiming of onset of cognitive decline: results from Whitehall II prospective cohort study
Singh-Manoux, A., Kivimaki, M., Glymour, M. M., Elbaz, A., Berr, C., Ebmeier, K. P., Ferrie, J. E., & Dugravot, A. (2012) · BMJ · doi:10.1136/bmj.d7622 · Cited by 836 · cited 1×
“The decreased cognitive performance begins around midlife from 45 years [173] and increases with age due to structural and functional changes in the brain (for instance, regional brain volumes and integrity of the white matter, reduction in the fluidity of brain membranes, and changes in lipid composition) [163,174–17…”
BackgroundComparison of Treatment Effects between Animal Experiments and Clinical Trials: Systematic Review
Perel, P., Roberts, I., Sena, E., Wheble, P., Briscoe, C., Sandercock, P., Macleod, M., Mignini, L. E., Jayaram, P., & Khan, K. S. (2007) · BMJ · doi:10.1136/bmj.39048.407928.be · Cited by 827 · cited 1×
“Animal models are required for studying both physiological and behavioral mechanisms of AD, but interspecies differences may result in unexpected results in clinical trials [123,124].”
BackgroundThe blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767
Clinical trial of blood-brain barrier disruption by pulsed ultrasound
Carpentier, A., Canney, M., Vignot, A., Reina, V., Beccaria, K., Horodyckid, C., Karachi, C., Leclercq, D., Lafon, C., Chapelon, J.-Y., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6086 · Cited by 757
A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., et al. (2000) · Nature · doi:10.1038/35050103 · Cited by 740
The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
Sengupta, U., Nilson, A. N., & Kayed, R. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.035 · Cited by 740 · cited 1×
“During the past decade, research efforts have focused on soluble Aβ oligomers (AβO), which appear to be a more toxic and disease-relevant form of Aβ [8,9].”
BackgroundFleminger, S. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.7.857 · Cited by 719
Johnsen, K. B., Gudbergsson, J. M., Skov, M. N., Pilgaard, L., Moos, T., & Duroux, M. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.005 · Cited by 704 · cited 1×
“Furthermore, their high biocompatibility and low immunogenicity enhance their uptake profile, their stability in systemic circulation, and their in vitro and in vivo therapeutic efficacy [229,230].”
BackgroundClinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702 · cited 1×
“However, in numerous human clinical trials using this approach, there was a decrease in amyloid load, but without significant clinical improvement nor reduction in disease progression [165].”
BackgroundDelivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679 · cited 1×
“Nevertheless, this approach is of interest for introducing slow-release implants or a colony of stem cells in the CNS for the timed release of therapeutic molecules [245].”
BackgroundFatty acid composition of brain phospholipids in aging and in Alzheimer’s disease
Söderberg, M., Edlund, C., Kristensson, K., & Dallner, G. (1991) · Lipids · doi:10.1007/bf02536067 · Cited by 667 · cited 16×
“Cholesterol and long-chain omega-3 FAs, and especially DHA, play major roles in brain function.”
BackgroundInfluentialAdapting liposomes for oral drug delivery
He, H., Lu, Y., Qi, J., Zhu, Q., Chen, Z., & Wu, W. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.06.005 · Cited by 663 · cited 1×
“Indeed, they offer better biocompatibility and safety than polymeric and metal-based nanoparticles due to their resemblance to biomembranes [204,205].”
BackgroundA 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer’s disease
Park, J., Wetzel, I., Marriott, I., Dréau, D., D’Avanzo, C., Kim, D. Y., Tanzi, R. E., & Cho, H. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0175-4 · Cited by 644
Intranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628 · cited 2×
“Because pathogenic soluble aggregates of Aβ appear early in the sequence of AD, they can represent interesting targets for therapeutics and diagnostics [51].”
BackgroundAge, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
Is Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621
Finkel, S. I., Miller, S., Silva, J. C. E., Cohen, G., & Sartorius, N. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297003943 · Cited by 620 · cited 1×
“As a result, in 1996, the concept of behavioral and psychological symptoms of dementia was presented by the International Psychogeriatric Association to designate symptoms of disturbance of perception, the content of thought, mood, and behavior frequently appearing in subjects with ND [46].”
BackgroundExosomes and Exosome-Inspired Vesicles for Targeted Drug Delivery
Antimisiaris, S. G., Mourtas, S., & Marazioti, A. (2018) · doi:10.20944/preprints201810.0507.v1 · Cited by 605
Exosomes and Exosome-Inspired Vesicles for Targeted Drug Delivery
Antimisiaris, S. G., Mourtas, S., & Marazioti, A. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040218 · Cited by 603
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588 · cited 1×
“However, these treatments, whose effectiveness is only partial and temporary at best, affect only the consequences of AD rather than the cause [1,17,157,158].”
BackgroundDrug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571 · cited 2×
“Drug development has targeted amyloid plaque formation, but other novel targets need to be explored [155].”
BackgroundAir Pollution and Dementia: A Systematic Review
Peters, R., Ee, N., Peters, J., Booth, A., Mudway, I., & Anstey, K. J. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180631 · Cited by 548
Ligand-targeted liposome design: challenges and fundamental considerations
Noble, G. T., Stefanick, J. F., Ashley, J. D., Kiziltepe, T., & Bilgicer, B. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.09.007 · Cited by 542 · cited 1×
“Another strategy is to bind nutrients, such as glucose and glutathione, to the surface of liposome to facilitate its translocation via carrier-mediated transcytosis [216].”
BackgroundDeckers, K., van Boxtel, M. P. J., Schiepers, O. J. G., de Vugt, M., Muñoz Sánchez, J. L., Anstey, K. J., Brayne, C., Dartigues, J.-F., Engedal, K., Kivipelto, M., et al. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4245 · Cited by 534
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526
Essential fatty acids and the brain: possible health implications
Youdim, K. A., Martin, A., & Joseph, J. A. (2000) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(00)00013-7 · Cited by 517 · cited 1×
“Two specific PUFAs, linoleic (LA, C18:2n-6) and alpha linolenic (ALA, C18:3n-3) acids, are essential since the body is unable to synthesize these fatty acids, and the only way to obtain them is from dietary sources [177].”
BackgroundBrain barrier systems: a new frontier in metal neurotoxicological research
Zheng, W., Aschner, M., & Ghersi-Egea, J.-F. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(03)00251-5 · Cited by 507 · cited 1×
“Conversely, molecules such as drugs, amino acids, and glucose are polar, hydrophilic, or possess a high electric charge to cross the BBB through active transport routes that depend on specific proteins [193].”
BackgroundExosomes: New players in cell–cell communication
Bang, C., & Thum, T. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.08.007 · Cited by 505 · cited 1×
“The exosomal content depends on the originating cell or organism, but in general, all exosomes contain non-coding RNAs, microRNAs, mRNAs, small molecule metabolites, proteins, and lipids [231].”
BackgroundTargeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles
Saint-Pol, J., Gosselet, F., Duban-Deweer, S., Pottiez, G., & Karamanos, Y. (2020) · Cells · doi:10.3390/cells9040851 · Cited by 503 · cited 3×
“The transport of exosomes across the BBB has been hypothesized to be through [33]: (1) nonspecific/lipid raft; (2) macropinocytosis; (3) cell signaling induced by the adhesion and fusion of exosomes to the cell surface, which causes the release of the exosomal content; (4) a signaling cascade induced by the associatio…”
BackgroundWang, P., Wang, H., Huang, Q., Peng, C., Yao, L., Chen, H., Qiu, Z., Wu, Y., Wang, L., & Chen, W. (2019) · Theranostics · doi:10.7150/thno.30716 · Cited by 494
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
Turturici, G., Tinnirello, R., Sconzo, G., & Geraci, F. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00228.2013 · Cited by 483
Yu, J.-T., Xu, W., Tan, C.-C., Andrieu, S., Suckling, J., Evangelou, E., Pan, A., Zhang, C., Jia, J., Feng, L., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321913 · Cited by 482
Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine
Fais, S., O’Driscoll, L., Borras, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro da Silva, A., Del Portillo, H., El Andaloussi, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b08015 · Cited by 481 · cited 2×
“In addition, their surface contains valuable receptors responsible for the identification of exosomes and the transportation of encapsulated materials to recipient cells [232].”
BackgroundMucke, L. (2009) · Nature · doi:10.1038/461895a · Cited by 456
Practical considerations for choosing a mouse model of Alzheimer’s disease
Jankowsky, J. L., & Zheng, H. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0231-7 · Cited by 449 · cited 2×
“The genetic utations found in and risk factors associated ith S have provided useful infor ation to develop ani al odels, particularly in mice [150].”
BackgroundBazan, N. G., Molina, M. F., & Gordon, W. C. (2011) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104635 · Cited by 441
Current and Novel Polymeric Biomaterials for Neural Tissue Engineering
Boni, R., Ali, A., Shavandi, A., & Clarkson, A. N. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0491-8 · Cited by 439 · cited 1×
“3D models include neurospheroids [120], organ-on-a-chip devices [121], and engineered brain tissue [122], mimicking the brain’s complexity; however, they are more difficult to engineer and maintain [123].”
BackgroundVieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Animal Models of Alzheimer Disease
LaFerla, F. M., & Green, K. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006320 · Cited by 419 · cited 2×
“This allows not only targeted genetic modifications related to AD pathology but also the evaluation of associated cognitive deficits [151].”
BackgroundDesign strategies and application progress of therapeutic exosomes
Liu, C., & Su, C. (2019) · Theranostics · doi:10.7150/thno.30853 · Cited by 415 · cited 1×
“Exosomes’ smart targeting behavior of specific receptors is governed by the donor cells in the form of lipid and cellular adhesion molecules found on their surfaces [228].”
BackgroundDocosahexaenoic acid promotes neurogenesis in vitro and in vivo
Kawakita, E., Hashimoto, M., & Shido, O. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.01.021 · Cited by 410 · cited 1×
“Several studies have demonstrated their potential neuroprotective role in neuron function and synapse plasticity [25].”
BackgroundDocosahexaenoic Acid and Cognition throughout the Lifespan
Weiser, M., Butt, C., & Mohajeri, M. (2016) · Nutrients · doi:10.3390/nu8020099 · Cited by 400 · cited 1×
“DHA can influence cellular and physiological processes, including membrane fluidity, the release of neurotransmitters, myelination, neuroinflammation, and neuronal differentiation and growth [183].”
BackgroundNixon, R. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700359 · Cited by 400 · cited 1×
“Other factors, including abnormal lipid and glucose metabolism, neuroinflammation, cerebrovascular abnormalities [53], and endosomal pathway blockade [54], can also contribute to AD pathology in the brain [55].”
BackgroundNutrition in Brain Development and Aging: Role of Essential Fatty Acids
Uauy, R., & Dangour, A. D. (2006) · Nutrition Reviews · doi:10.1301/nr.2006.may.s24-s33 · Cited by 395
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
Lanctôt, K. L., Amatniek, J., Ancoli‐Israel, S., Arnold, S. E., Ballard, C., Cohen‐Mansfield, J., Ismail, Z., Lyketsos, C., Miller, D. S., Musiek, E., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.07.001 · Cited by 395
Martins, I. J., Hone, E., Foster, J. K., Sünram-Lea, S. I., Gnjec, A., Fuller, S. J., Nolan, D., Gandy, S. E., & Martins, R. N. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001854 · Cited by 388 · cited 2×
“Increased brain cholesterol levels and dyslipidemias overall have been linked to AD incidence [49,55,100,107].”
BackgroundCholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease
Mesulam, M. ‐. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23415 · Cited by 375 · cited 1×
“Initially, before the apparition of Aβ plaques and NFT, the presence of soluble aggregates of Aβ led to the destruction of synapses, dendritic spines and neurons, dysfunction of major system neurotransmitters in the central nervous system, and glutamate and acetylcholine [61].”
BackgroundThe emerging role of exosomes in mental disorders
Saeedi, S., Israel, S., Nagy, C., & Turecki, G. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0459-9 · Cited by 370
Liposomes: A Review of Manufacturing Techniques and Targeting Strategies
Maherani, B., Arab-Tehrany, E., R. Mozafari, M., Gaiani, C., & Linder, M. (2011) · Current Nanoscience · doi:10.2174/157341311795542453 · Cited by 369 · cited 1×
“NLs are spherical and closed vesicles with diameters in the nanometer range, formed by phospholipid bilayers dispersed in an aqueous medium [38,39].”
BackgroundSelf-citationInsights into Direct Nose to Brain Delivery: Current Status and Future Perspective
Mittal, D., Ali, A., Md, S., Baboota, S., Sahni, J. K., & Ali, J. (2014) · Drug Delivery · doi:10.3109/10717544.2013.838713 · Cited by 359
Horrocks, L. A., & Farooqui, A. A. (2004) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.12.011 · Cited by 356 · cited 1×
“Since diet is an important source of these PUFA, nutritionally-based prevention strategies can be used towards optimizing CNS lipid status [26].”
BackgroundAgrawal, M., Ajazuddin, Tripathi, D. K., Saraf, S., Saraf, S., Antimisiaris, S. G., Mourtas, S., Hammarlund-Udenaes, M., & Alexander, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.019 · Cited by 356 · cited 4×
“Soft NP, such as nanoliposomes (NL) or exosomes, represent one of the most effective drug delivery processes to be able to protect therapeutic agents and deliver them to the target tissues [32,33].”
BackgroundMethodInfluentialInvolvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353 · cited 2×
“Research shows that the imbalance of lipid homeostasis is associated with a high risk of AD [105,106].”
BackgroundCurrent approaches to enhance CNS delivery of drugs across the brain barriers
Lu, C.-T., Zhao, Y.-Z., Wong, H. L., Cai, J., Peng, L., & Tian, X.-Q. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61288 · Cited by 350 · cited 2×
“Another challenge in AD treatments is the efficient delivery and targeting of molecules of interest to the brain due to the protective barriers of the central nervous system [27,28].”
BackgroundFotuhi, M., Mohassel, P., & Yaffe, K. (2009) · Nature Reviews Neurology · doi:10.1038/ncpneuro1044 · Cited by 344
Loy, C. T., Schofield, P. R., Turner, A. M., & Kwok, J. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60630-3 · Cited by 342
Lipid rafts, cholesterol, and the brain
Korade, Z., & Kenworthy, A. K. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.02.019 · Cited by 342 · cited 1×
“Increased brain cholesterol levels and dyslipidemias overall have been linked to AD incidence [49,55,100,107].”
BackgroundPSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease
Oksanen, M., Petersen, A. J., Naumenko, N., Puttonen, K., Lehtonen, Š., Gubert Olivé, M., Shakirzyanova, A., Leskelä, S., Sarajärvi, T., Viitanen, M., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.016 · Cited by 332
Rosenberg, A., Mangialasche, F., Ngandu, T., Solomon, A., & Kivipelto, M. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.41 · Cited by 316
Depressive Symptoms and Cognitive Decline in Late Life: A Prospective Epidemiological Study
Ganguli, M., Du, Y., Dodge, H. H., Ratcliff, G. G., & Chang, C.-C. H. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.153 · Cited by 314 · cited 1×
“Symptoms of depression, anxiety, stress, and chronic psychological distress have also been associated with an increased risk of MCI and AD [114,115].”
BackgroundSpector, A. A. (1999) · Lipids · doi:10.1007/bf02562220 · Cited by 310
Intranasal Treatment of Central Nervous System Dysfunction in Humans
Chapman, C. D., Frey, W. H., Craft, S., Danielyan, L., Hallschmid, M., Schiöth, H. B., & Benedict, C. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0915-1 · Cited by 310
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309
The interplay of neurotransmitters in Alzheimer's disease
Francis, P. T. (2005) · CNS Spectrums · doi:10.1017/s1092852900014164 · Cited by 302 · cited 1×
“Indeed, glutamatergic and cholinergic deficits are strongly correlated with cognitive deterioration in AD [63].”
BackgroundDjupesland, P. G., Messina, J. C., & Mahmoud, R. A. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.41 · Cited by 295 · cited 1×
“This approach is increasingly used in clinical studies for the treatment of neurological diseases [251] like AD [32,252], brain injuries [253], and autism [254].”
MethodAndrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293
Nanoliposome technology for the food and nutraceutical industries
Khorasani, S., Danaei, M., & Mozafari, M. R. (2018) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2018.07.009 · Cited by 293 · cited 1×
“NLs are spherical and closed vesicles with diameters in the nanometer range, formed by phospholipid bilayers dispersed in an aqueous medium [38,39].”
BackgroundBurgess, A., Dubey, S., Yeung, S., Hough, O., Eterman, N., Aubert, I., & Hynynen, K. (2014) · Radiology · doi:10.1148/radiol.14140245 · Cited by 286 · cited 1×
“A magnetic resonance guide can be a good solution to focus ultrasound in combination with intravenously injected microbubbles in order to transiently open the BBB and reduce Aβ and τau pathology in animal models of AD [258].”
BackgroundTargeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse
Liu, Y., Li, D., Liu, Z., Zhou, Y., Chu, D., Li, X., Jiang, X., Hou, D., Chen, X., Chen, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep17543 · Cited by 280 · cited 1×
“treated morphine addiction using exosomes expressing RVG peptide loaded with opioid receptor mu (MOR) siRNA [240].”
MethodAmyloid β-protein oligomers and Alzheimer’s disease
Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276
Sexual dimorphism in predisposition to Alzheimer's disease
Fisher, D. W., Bennett, D. A., & Dong, H. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.04.004 · Cited by 270
A 3D human neural cell culture system for modeling Alzheimer's disease
Kim, Y. H., Choi, S. H., D'Avanzo, C., Hebisch, M., Sliwinski, C., Bylykbashi, E., Washicosky, K. J., Klee, J. B., Brüstle, O., Tanzi, R. E., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.065 · Cited by 269 · cited 1×
“Human NPCs were used to form differentiated 3D neurospheroids with Aβ aggregation, modeling AD [149].”
MethodCenteno, E. G. Z., Cimarosti, H., & Bithell, A. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0258-4 · Cited by 268
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266 · cited 1×
“Other applications that also need to be considered include the use of gene editing for AD treatment [267,268], as well as antibody therapy targeting Aβ and tau proteins [269].”
BackgroundMourtas, S., Lazar, A. N., Markoutsa, E., Duyckaerts, C., & Antimisiaris, S. G. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.050 · Cited by 263
Modifiable Risk Factors for Alzheimer’s Disease
Edwards III, G. A., Gamez, N., Escobedo Jr., G., Calderon, O., & Moreno-Gonzalez, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00146 · Cited by 253
A 3D human brain–like tissue model of herpes-induced Alzheimer’s disease
Cairns, D. M., Rouleau, N., Parker, R. N., Walsh, K. G., Gehrke, L., & Kaplan, D. L. (2020) · Science Advances · doi:10.1126/sciadv.aay8828 · Cited by 247
Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting
Liu, Y., Ran, R., Chen, J., Kuang, Q., Tang, J., Mei, L., Zhang, Q., Gao, H., Zhang, Z., & He, Q. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.031 · Cited by 246
Tolar, M., Hey, J., Power, A., & Abushakra, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126355 · Cited by 243 · cited 1×
“AβO are considered to be pathological agents that appear before the first neuropathological signs of AD [10,11].”
BackgroundDubois, B., Epelbaum, S., Nyasse, F., Bakardjian, H., Gagliardi, G., Uspenskaya, O., Houot, M., Lista, S., Cacciamani, F., Potier, M.-C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30029-2 · Cited by 237
The relationship between stress and Alzheimer's disease
Justice, N. J. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.04.002 · Cited by 237 · cited 1×
“Symptoms of depression, anxiety, stress, and chronic psychological distress have also been associated with an increased risk of MCI and AD [114,115].”
BackgroundNanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies
Pires, P. C., & Santos, A. O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.047 · Cited by 228 · cited 1×
“Drugs can be directly administrated through the IN route to the CNS via the olfactory mucosa [249].”
BackgroundDysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers
Wong, M. W., Braidy, N., Poljak, A., Pickford, R., Thambisetty, M., & Sachdev, P. S. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.008 · Cited by 223
Peeraer, E., Bottelbergs, A., Van Kolen, K., Stancu, I.-C., Vasconcelos, B., Mahieu, M., Duytschaever, H., Ver Donck, L., Torremans, A., Sluydts, E., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.032 · Cited by 214 · cited 2×
“Injection in tauP301L transgenic mice resulted in elevated p-tau levels close to the site of injection [143].”
BackgroundClarke, J. R., Lyra e Silva, N. M., Figueiredo, C. P., Frozza, R. L., Ledo, J. H., Beckman, D., Katashima, C. K., Razolli, D., Carvalho, B. M., Frazão, R., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404183 · Cited by 214 · cited 1×
“Moreover, intracerebroventricular (ICV) administration of Aβ oligomers into mice shows a failure to induce glucose intolerance, indicating Aβ oligomers target metabolic control [152].”
BackgroundCognitive reserve and long-term change in cognition in aging and preclinical Alzheimer's disease
Soldan, A., Pettigrew, C., Cai, Q., Wang, J., Wang, M.-C., Moghekar, A., Miller, M. I., & Albert, M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.002 · Cited by 205
Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
Teleanu, R. I., Preda, M. D., Niculescu, A.-G., Vladâcenco, O., Radu, C. I., Grumezescu, A. M., & Teleanu, D. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050987 · Cited by 200 · cited 1×
“Another challenge in AD treatments is the efficient delivery and targeting of molecules of interest to the brain due to the protective barriers of the central nervous system [27,28].”
BackgroundLiposome delivery systems for the treatment of Alzheimer’s disease
Ross, C., Taylor, M., Fullwood, N., & Allsop, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s183117 · Cited by 198 · cited 2×
“Furthermore, nanotechnology can be used to improve the bioavailability of PUFA in the form of NL [34,37].”
BackgroundLee, H.-K., Velazquez Sanchez, C., Chen, M., Morin, P. J., Wells, J. M., Hanlon, E. B., & Xia, W. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163072 · Cited by 190 · cited 2×
“used iPSCs from various AD patients’ blood to form Aβ oligomers in neuro-spheroids, which provide a platform for high throughput testing of AD drugs [137].”
MethodNew Approaches for the Treatment of Alzheimer’s Disease
Fish, P. V., Steadman, D., Bayle, E. D., & Whiting, P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.034 · Cited by 189
A Wirelessly Controlled Smart Bandage with 3D‐Printed Miniaturized Needle Arrays
Derakhshandeh, H., Aghabaglou, F., McCarthy, A., Mostafavi, A., Wiseman, C., Bonick, Z., Ghanavati, I., Harris, S., Kreikemeier‐Bower, C., Moosavi Basri, S. M., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201905544 · Cited by 188
Self-citationAberrant iPSC-derived human astrocytes in Alzheimer's disease
Jones, V. C., Atkinson-Dell, R., Verkhratsky, A., & Mohamet, L. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.89 · Cited by 186 · cited 2×
“PSEN1 M146L mutated hiPSC-derived astrocytes Disturbed expression of astrocyte markers [129]”
BackgroundMethodDrug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184 · cited 1×
“The BBB represents a challenge for CNS drug delivery, and many strategies have been developed to address this challenge [162].”
BackgroundAβ-independent processes—rethinking preclinical AD
Chételat, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.21 · Cited by 184 · cited 1×
“Indeed, amyloid pathology and tauopathy have been shown to appear independently under the influence of genetic and environmental factors [59,60].”
BackgroundBrain injury biomarkers are not dependent on β‐amyloid in normal elderly
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23816 · Cited by 183 · cited 1×
“Indeed, amyloid pathology and tauopathy have been shown to appear independently under the influence of genetic and environmental factors [59,60].”
BackgroundNose-to-brain peptide delivery – The potential of nanotechnology
Samaridou, E., & Alonso, M. J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.001 · Cited by 178 · cited 1×
“Recent studies have analyzed the direct transport of proteins and peptides via IN [250].”
BackgroundSpuch, C., & Navarro, C. (2011) · Journal of Drug Delivery · doi:10.1155/2011/469679 · Cited by 177 · cited 1×
“Even though conventional liposomes cannot cross the BBB, modifying their surface can enable them to pass through and unload their cargo directly into the CNS [206].”
BackgroundCummings, J., Ritter, A., & Zhong, K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179901 · Cited by 176
Thomas, J., Thomas, C. J., Radcliffe, J., & Itsiopoulos, C. (2015) · BioMed Research International · doi:10.1155/2015/172801 · Cited by 173 · cited 1×
“Long-chain n-3 FA supplementation in the early stages of AD has shown promising potential [111].”
BackgroundAdiposity, hyperinsulinemia, diabetes and Alzheimer's disease
Luchsinger, J. A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.048 · Cited by 171 · cited 1×
“Dyslipidemias are also associated with obesity, which has been linked to insulin resistance/hyperinsulinemia in the development of AD [108,109].”
BackgroundChange in risk of Alzheimer disease over time
Hebert, L. E., Bienias, J. L., Aggarwal, N. T., Wilson, R. S., Bennett, D. A., Shah, R. C., & Evans, D. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f0754f · Cited by 158 · cited 1×
“Indeed, increased life expectancy is correlated with a higher probability of developing neurodegenerative diseases, including AD [89,90].”
BackgroundReed, M. J., Damodarasamy, M., & Banks, W. A. (2019) · Tissue Barriers · doi:10.1080/21688370.2019.1651157 · Cited by 157
Beach, T. G., Kuo, Y.-M., Spiegel, K., Emmerling, M. R., Sue, L. I., Kokjohn, K., & Roher, A. E. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.4.308 · Cited by 154 · cited 1×
“The cholinergic deficit sets in early histopathologic stage of AD, before the presence of clinical symptoms [64].”
BackgroundAPOE Genotype and Neuroimaging Markers of Alzheimer’s Disease: Systematic Review and Meta-Analysis
Liu, Y., Yu, J.-T., Wang, H.-F., Han, P.-R., Tan, C.-C., Wang, C., Meng, X.-F., Risacher, S. L., Saykin, A. J., & Tan, L. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307719 · Cited by 152 · cited 1×
“The ε4 allele is a genetic risk factor of SAD involved with a high risk of AD, found to be associated with atrophic hippocampal volume, abnormal accumulation of Aβ protein and increased amyloid deposits, and cerebral hypometabolism [95].”
BackgroundKwak, S. S., Washicosky, K. J., Brand, E., von Maydell, D., Aronson, J., Kim, S., Capen, D. E., Cetinbas, M., Sadreyev, R., Ning, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15120-3 · Cited by 151
Ivanyuk, D., Pérez, M. J., Panagiotakopoulou, V., Di Napoli, G., Brunetti, D., Al-Shaana, R., Kaeser, S. A., Jucker, M., Zeviani, M., Viscomi, C., et al. (2020) · doi:10.1101/2020.01.27.919522 · Cited by 145
Pérez, M. J., Ivanyuk, D., Panagiotakopoulou, V., Di Napoli, G., Kalb, S., Brunetti, D., Al-Shaana, R., Kaeser, S. A., Fraschka, S. A.-K., Jucker, M., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0807-4 · Cited by 144 · cited 1×
“used human iPSC with a loss of PITRM1 function (Pitrilysin metallopeptidase 1), an enzyme involved in mitochondrial degradation associated with AD, as a 2D model and to form 3D organoids [146].”
MethodMetabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease
Kang, S., Lee, Y.-H., & Lee, J. E. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.3.479 · Cited by 143 · cited 2×
“from [65], Copyright 2017, Yonsei Univ rsity College of Medicine.”
MethodPapadimitriou, C., Celikkaya, H., Cosacak, M. I., Mashkaryan, V., Bray, L., Bhattarai, P., Brandt, K., Hollak, H., Chen, X., He, S., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.06.005 · Cited by 143 · cited 2×
“System could allow for identification of therapeutic targets [135]”
BackgroundMethodCummings, J. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.05.006 · Cited by 140 · cited 1×
“Moreover, topographical markers for AD include volume modifications in the brain (temporoparietal, hippocampal atrophy, cortical thickness) assessed by magnetic resonance imaging (MRI) and glucose hypometabolism measured by fluorodeoxyglucose (FDG)-PET [73].”
MethodDEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE
Cummings, J., & Fox, N. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.12 · Cited by 139
Soft‐Nanoparticle Functionalization of Natural Hydrogels for Tissue Engineering Applications
Elkhoury, K., Russell, C. S., Sanchez‐Gonzalez, L., Mostafavi, A., Williams, T. J., Kahn, C., Peppas, N. A., Arab‐Tehrany, E., & Tamayol, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900506 · Cited by 138 · cited 1×
“Liposomes generally consist of a lipid bilayer encircling an aqueous core [199,200].”
BackgroundSelf-citationLactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery
Chen, H., Tang, L., Qin, Y., Yin, Y., Tang, J., Tang, W., Sun, X., Zhang, Z., Liu, J., & He, Q. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.03.007 · Cited by 136 · cited 1×
“Lf-modified liposomes have also been created to cross the BBB via receptor-mediated transcytosis [211,212].”
BackgroundHasan, M., Elkhoury, K., Kahn, C. J. F., Arab-Tehrany, E., & Linder, M. (2019) · Molecules · doi:10.3390/molecules24102023 · Cited by 133 · cited 2×
“Liposomes are able to encapsulate hydrophobic drugs in their bilayer and hydrophilic bioactive molecules in their core [201].”
BackgroundSelf-citation3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
Choi, S. H., Kim, Y. H., Quinti, L., Tanzi, R. E., & Kim, D. Y. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0139-7 · Cited by 132 · cited 1×
“Organoids, or other forms of 3D cell culture, can simulate AD pathology, as they are able to secrete sufficient levels of Aβ42 to form Aβ plaques and form NFT, unlike 2D cultures [148].”
BackgroundKoch, P., Tamboli, I. Y., Mertens, J., Wunderlich, P., Ladewig, J., Stüber, K., Esselmann, H., Wiltfang, J., Brüstle, O., & Walter, J. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.02.012 · Cited by 129 · cited 11×
“2D in vitro models hESC-derived neurons overexpressing PSEN1 Increased Aβ42/40 ratio due to depletion of Aβ40 [125]”
BackgroundInfluentialvan Wijk, N., Broersen, L. M., de Wilde, M. C., Hageman, R. J. J., Groenendijk, M., Sijben, J. W. C., & Kamphuis, P. J. G. H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130998 · Cited by 128
Elkhoury, K., Koçak, P., Kang, A., Arab-Tehrany, E., Ellis Ward, J., & Shin, S. R. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090849 · Cited by 128 · cited 1×
“Liposomes can be classified as conventional, PEGylated/stealth, or ligand-targeted based on the characteristics of their surface [202].”
BackgroundSelf-citationPrecision Nanomedicine in Neurodegenerative Diseases
Goldsmith, M., Abramovitz, L., & Peer, D. (2014) · ACS Nano · doi:10.1021/nn501292z · Cited by 124
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Cano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00864-x · Cited by 122
Martín-Maestro, P., Gargini, R., A. Sproul, A., García, E., Antón, L. C., Noggle, S., Arancio, O., Avila, J., & García-Escudero, V. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00291 · Cited by 120 · cited 2×
“used hiPSC-derived neurons with a PSEN1 A246E mutation to show the role of mitochondrial dysfunction in AD [130].”
BackgroundMethodThe blood brain barrier in Alzheimer’s disease
Chakraborty, A., de Wit, N. M., van der Flier, W. M., & de Vries, H. E. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2016.11.008 · Cited by 118
Wickner, R. B., Edskes, H. K., Gorkovskiy, A., Bezsonov, E. E., & Stroobant, E. E. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1016/bs.adgen.2015.12.003 · Cited by 116
Research works printed but not linked: 1
- Prince, M.J., Guerchet, M.M., and Prina, M. (2022, June 04). The Epidemiology and Impact of Dementia: Current State and Future Trends. WHO Thematic Briefing. Available online: https://hal.archives-ouvertes.fr/hal-03517019.
Cited by
Kale, M., Wankhede, N., Pawar, R., Ballal, S., Kumawat, R., Goswami, M., Khalid, M., Taksande, B., Upaganlawar, A., Umekar, M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102497 · Cited by 183
Su, W.-M., Gu, X.-J., Dou, M., Duan, Q.-Q., Jiang, Z., Yin, K.-F., Cai, W.-C., Cao, B., Wang, Y., & Chen, Y.-P. (2023) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331142 · Cited by 161
Amyloid Precursor Protein and Alzheimer’s Disease
Orobets, K. S., & Karamyshev, A. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914794 · Cited by 141
“It is predicted that a dramatic elevation of AD pathology will occur in the future, with 13.85 million Americans affected by Alzheimer’s dementia and 152 million affected around the world by the year 2050 [2,3].”
InfluentialBeltrán-Velasco, A. I., & Clemente‐Suárez, V. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062440 · Cited by 137
“There are significant unmet needs in the effective modulation of neuroinflammation and BBB dysfunction, particularly in the context of systemic inflammatory responses [97].”
Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders
Cohen, J., Mathew, A., Dourvetakis, K. D., Sanchez-Guerrero, E., Pangeni, R. P., Gurusamy, N., Aenlle, K. K., Ravindran, G., Twahir, A., Isler, D., et al. (2024) · Cells · doi:10.3390/cells13060511 · Cited by 103
“Cholinesterase inhibitors work by increasing the neurotransmitter acetylcholine (Ach) in the brain to address the deficiency in AD patients and thus help in the transmission of information between neurons [4].”
BackgroundInfluential
Metadata
- Authors
- Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E.
- Affiliations
- Laboratoire Animal et Agroécosystèmes (FR)
- Laboratoire d'Ingénierie des Biomolécules (FR)
- University of Twente (NL)
- UConn Health (US)
- LIBio Laboratory, University of Lorraine, 54505 Vandoeuvre-lès-Nancy, France
- Corresponding author
- Yen, Frances T.
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-11-12
- Volume
- 23
- Issue
- 22
- Pages
- 13954
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9697769
- OpenAlex
- W4309008621
- Semantic Scholar
- 9dbe6b562aec1dc05309ecc0b7a89b81e6fd01bf
- Cited by
- 689
- References
- 279
- Citations by year
- 2026: 204 · 2025: 255 · 2024: 171 · 2023: 58 · 2022: 1
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Twente Research Information (publishedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Twente Research Information (submittedVersion, cc-by)
- Funders
- Agence Nationale de la Recherche (ANR-15-IDEX-0004)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, Alzheimer's disease prevention, risk factors, disease-modifying therapy, brain drug delivery, blood-brain barrier, nanoliposomes, exosomes, nanoparticles, intranasal administration
- MeSH terms
- Alzheimer Disease, Blood-Brain Barrier, Humans, Drug Delivery Systems, Neurodegenerative Diseases, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.